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Abstract
Aims: Chronic metabolic impairment and oxidative stress are associated with the pathogenesis of axonal dys-
function in a growing number of neurodegenerative conditions. To investigate the intertwining of both noxious
factors, we have chosen the mouse model of adrenoleukodystrophy (X-ALD), which exhibits axonal degener-
ation in spinal cords and motor disability. The disease is caused by loss of function of the ABCD1 transporter,
involved in the import and degradation of very long-chain fatty acids (VLCFA) in peroxisomes. Oxidative stress
due to VLCFA excess appears early in the neurodegenerative cascade. Results: In this study, we demonstrate by
redox proteomics that oxidative damage to proteins specifically affects five key enzymes of glycolysis and TCA
(Tricarboxylic acid) cycle in spinal cords of Abcd1 - mice and pyruvate kinase in human X-ALD fibroblasts. We
also show that NADH and ATP levels are significantly diminished in these samples, together with decrease of
pyruvate kinase activities and GSH levels, and increase of NADPH. Innovation: Treating Abcd1 - mice with the
antioxidants N-acetylcysteine and a-lipoic acid (LA) prevents protein oxidation; preserves NADH, NADPH,
ATP, and GSH levels; and normalizes pyruvate kinase activity, which implies that oxidative stress provoked by
VLCFA results in bioenergetic dysfunction, at a presymptomatic stage. Conclusion: Our results provide mecha-
nistic insight into the beneficial effects of antioxidants and enhance the rationale for translation into clinical trials
for X-adrenoleukodystrophy. Antioxid. Redox Signal. 15, 2095–2107.
Introduction
Impaired bioenergetics and mitochondria metabolism,together with oxidative stress, are commonalities underly-
ing age-related neurodegenerative diseases, such as Parkin-
son’s (PD), Huntington’s (HD) and Alzheimer’s (AD) disease,
Friedreich’s ataxia, or amyotrophic lateral sclerosis (ALS), to
cite a few (11, 12, 14, 29, 36, 37, 40). It has been postulated that
oxidative stress in mitochondria can reduce the activities of
their various proteins due to oxidative modifications (8, 32,
43, 60, 65). Oxidative stress can also provoke mutations in the
mtDNA, which is more sensitive than nuclear DNA to reactive
oxygen species (ROS) (45). Both mtDNA and protein modifi-
cations may result in a metabolic failure characterized by an
increase in NAD + /NADH ratio (i.e., a decrease in cellular
reducing potential), which is a powerful regulator of glycolysis,
TCA cycle, and oxidative phosphorylation (69) and also in re-
duced levels of ATP (16, 23).
Here we sought to investigate energy homeostasis in a
model of axonal degeneration caused by oxidative stress of a
known etiology, the mouse model of X-linked adrenoleuko-
dystrophy (X-ALD: McKusick no. 300100). This is a rare and
fatal disease characterized by central inflammatory demye-
lination in the brain or slowly progressive spastic paraparesis,
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as a consequence of axonal degeneration in the spinal cord (17,
42). X-ALD is the most frequently inherited leukodystrophy,
with a minimum incidence of 1 in 17,000 men. All patients
have mutations in the gene encoding the ABCD1 protein
(NM_000033), an ATP binding cassette peroxisomal trans-
porter involved in the importing of very long-chain fatty acids
(VLCFA, C ‡ 22:0) and VLCFA-CoA esters into the peroxi-
some for degradation (66). Defective function of the ABCD1
transporter leads to VLCFA accumulation in most organs and
plasma; and elevated levels of VLCFA are used as a biomarker
for the biochemical diagnosis of the disease. Classical inacti-
vation of ABCD1 in the mouse results in late onset neurode-
generation with axonopathy in spinal cord, in the absence of
inflammatory demyelination in the brain, resembling the
most frequent X-ALD phenotype or adrenomyeloneuropathy
(49, 50). Oxidative damage has been evidenced in postmortem
brain samples from individuals with cerebral ALD (24) and in
mouse spinal cords before disease onset (20). Further, we re-
cently reported compelling evidence that a combination of
antioxidants halts clinical progression and reverses axonal
damage in X-ALD mouse model, thereby providing formal
conceptual proof that oxidative injury is a major etiopatho-
genic factor in this disease (38). The source of this oxidative
damage is most likely an excess of saturated and unsaturated
VLCFA, which are known to generate free radicals and cause
oxidative damage to proteins in cell culture (20, 22).
In this study, we demonstrate by a redox proteomics ap-
proach that ABCD1 ablation induces the oxidation of en-
zymes of glycolysis and TCA cycle in spinal cords. This
oxidation inactivates the affected enzymes, and bioenergetic
failure is manifested by decreased levels of cellular NADH
and ATP, together with decreased levels of GSH. All these
changes occur months before disease onset. Additionally,
we provide evidence that the combination of antioxidants
N-acetylcysteine and a-lipoic acid prevents protein oxidation
and metabolic failure in spinal cords.
Results
ABCD1 loss induces the specific oxidation of glycolysis
and tricarboxylic acid cycle enzymes in spinal cord
We pointed out earlier that oxidative damage is a main
etiopathogenic factor in X-ALD mouse model (20, 38). This
damage is characterized by an increase in the markers of li-
poxidation to proteins (MDA-lysine), combined with markers
of glycoxidation and lipoxidation, carboxyethyl-lysine (CEL)
and carboxymethyl-lysine (CML), together with markers of
direct carbonylation of proteins (glutamic semialdehyde
[GSA] and aminoadipic semialdehyde [AASA]), in spinal
cords and in peripheral mononuclear cells or fibroblasts de-
rived from patients with X-ALD (20, 22). Thus, we set out to
identify oxidation targets in spinal cords with a redox pro-
teomics approach (54).
Using this methodology (Fig. 1A and Supplementary
Table S1; Supplementary Data are available online at www
.liebertonline.com/ars), five oxidized proteins were pin-
pointed: aldolase A (ALDO A), phosphoglycerate kinase
(PGK1), pyruvate kinase (PKM2), dihydrolipoamide dehy-
drogenase (DLD), and mitochondrial aconitase (ACO2). To
confirm that the excised spot corresponded to the five identi-
fied proteins, we performed a 2D gel, then a western blot with
an antibody against each specific protein, with the same sam-
FIG. 1. ALDO A, PGK1, PKM2, DLD, and ACO2 are
more highly oxidized in spinal cord from 12 month-old
Abcd1 - mice. (A) Redox proteomics experiments in Wt and
Abcd1 - mice. Western blot with an antibody anti-DNP was
performed to identify oxidized proteins (n = 5/genotype). A
validation Western blot was performed with specific anti-
bodies against aldolase A (ALDO A), phosphoglycerate ki-
nase (PGK1), pyruvate kinase (PKM2), dihydrolipoamide
dehydrogenase (DLD), and mitochondrial aconitase (ACO2)
after identification obtained by MS (B), allowing relative
quantification of their expression (C). Relative protein level is
expressed as a percentage of control, and referred to c-tu-
bulin as loading marker. (D) Pkm2 was quantified by Q-PCR
in Wt and Abcd1 - mice. 36b4 was used as internal control
(n = 10–12 by genotype). Statistical analysis was done by
Student’s t-test: *p < 0.05.
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ples that were used in Figure 1A, both wild type and Abcd1 - .
Results are shown for the Abcd1- membrane (Fig. 1B). We also
quantified mRNA and protein expression levels and found that
pyruvate kinase is repressed in 12 month-old Abcd1 - spinal
cord (Fig. 1C, D). The expression of the four other oxidized
proteins was not modified in Abcd1 - mice (Fig. 1C).
C26:0 excess induces pyruvate kinase oxidative
inactivation in human fibroblasts
Earlier, we reported that the levels of lipoxidative (MDAL),
glycoxidative/lipoxidative (CEL, CML), and protein oxidative
(GSA; AASA) markers were about doubled in the fibroblasts
derived from patients with X-ALD (20). We also demonstrated
that excess C26:0 generates ROS in human fibroblasts (20) and
oxidative lesions to proteins in X-ALD fibroblasts. To identify
which proteins are oxidation targets in human X-ALD fibro-
blasts, we performed redox proteomics. We found that PKM2
is more oxidized in human X-ALD than in control fibroblasts
(Fig. 2A). To investigate whether C26:0 excess is involved in the
PKM2 oxidation, we also performed redox proteomics exper-
iments with cultured human nondiseased and X-ALD fibro-
blasts that were treated with a pathophysiologically relevant
dose of C26:0 (100 lM) for 7 days, as previously described (20).
We found that C26:0 excess induces PKM2 oxidation and in-
activation in both nondiseased and X-ALD fibroblasts (Fig.
2A). As control, we incubated X-ALD and nondiseased fibro-
blasts with 100 lM oleic acid (C18:1) and could not detect ox-
idation increases in 2D gels after DNP exposure (data not
shown). No signs of toxicity or reduced proliferation were seen
in the cultures. To confirm that the excised spot corresponded
to PKM2, we also performed a 2D gel, then a western blot with
an antibody against PKM2 (Fig. 2B and Supplementary Table
S1). Further, we quantified PKM2 gene expression and found
that it was neither affected by genotype nor by C26:0 excess in
human fibroblasts (Fig. 2C).
ABCD1 loss provokes specific glycolytic and TCA
cycle metabolic signature in spinal cord
Several reports indicate that oxidation of enzymes involved
in energy metabolism results in a decrease in their activity (8,
60, 65). To investigate whether enzyme activity is affected in
our model, we quantified substrates and/or products of the
five oxidized enzymes with a directed metabolomics approach.
We found that the level of fructose 1,6-bisphophate, the
substrate of ALDO A, was not modified in Abcd1 - spinal cord
(Fig. 3A and Table 1). However, its products—dihydroxyac-
etone phosphate (DHAP) and glyceraldehyde 3-phosphate
(GA3P)—were present at significantly lower levels in Abcd1 -
mice, which suggests that oxidation affected ALDO A activity
in vivo (Fig. 3A and Table 1). Lower levels of DHAP and GA3P
could also be explained by its nonenzymatic conversion to
methylglyoxate (MGO) (48), which can be degraded through
glyxolases and/or react with lysine residues in proteins. This
is consistent with the reported increase in carboxyethilisyne
FIG. 2. PKM2 is oxidized
by C26:0 excess in human fi-
broblasts. (A) Redox pro-
teomics experiments were
performed in human control
and X-ALD fibroblasts (n = 5
per genotype and condition),
which were treated for 7 days
with BSA-conjugated C26:0
(100 lM) or BSA as control in
a serum-free medium. Wes-
tern blot with an antibody
anti-DNP was performed to
identify oxidized proteins.
Western blot was performed
with a specific antibody against
pyruvate kinase (PKM2) to
validate the protein identifi-
cation obtained by MS (B) or
to quantify their expression
(C). Relative protein level is
expressed as a percentage
of control, and referred to c-
tubulin as loading marker.
Significant differences were
revealed by ANOVA fol-
lowed by Tukey HSD post hoc
test.
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(CEL) (20). 2-Phosphoglycerate and 3-Phosphoglycerate can-
not be distinguished by MS, but an m/z (mass-to-charge ra-
tio) ion compatible with their masses is lowered in spinal cord
from Abcd1 - mice, which suggests that activities of PGK1
(which produces 3-Phosphoglycerate) and/or Phosphogly-
cerate mutase (which converts 3-Phosphoglycerate into 2-
Phosphoglycerate) were modified (Fig. 3A). Since PGK1 was
found to be oxidized in our model, 3-Phosphoglycerate level
was likely decreased due to lower PGK1 activity (Fig. 3A).
Dihydrolipoamide dehydrogenase (DLD), a subunit of a-
ketoglutarate dehydrogenase complex (KGDHC) and of four
other important mitochondrial enzymes, was found to be ox-
idized, and the concentration of its substrate a-ketoglutarate
was increased in Abcd1 - spinal cord (Fig. 3A). Thus, we
hypothesized that KGDHC activity was most likely to be
decreased in Abcd1-null mice, even if the steady-state level of
a-ketoglutarate is also determined by several factors such as
glutamate availability and the rate-limiting enzyme in
KGDHC is not DLD but a-ketoglutarate dehydrogenase E1k.
Since DLD is also a subcomponent of pyruvate dehydroge-
nase complex (PDHC), it was expected that pyruvate catabo-
lism would also be altered. However, we found that pyruvate
level was not modified in Abcd1-null spinal cord. Although
lactate level and the pyruvate/lactate ratio are not modified in
Abcd1 - spinal cord, we found that PKM2 was oxidized and its
expression decreased in Abcd1- spinal cord (Fig. 3A, B). These
results indicate that steady-state level of pyruvate is main-
tained through a balanced decrease in its synthesis and deg-
radation, without lactate accumulation. This could be due, for
instance, to concerted decreased glycolytic production of py-
ruvate and its decreased uptake or oxidation in mitochondria.
We also found that citrate concentration was increased in
spinal cord from Abcd1-null mice, which suggests a defect in
citrate catabolism (Fig. 3A), likely due to the oxidative dam-
age to ACO2 in Abcd1 - mice (Fig. 3A).
Moreover, we also observed that (i) oxaloacetate (OAA),
fumarate, and malate levels are not affected and (ii) the en-
zymes involved in the production or degradation of these
metabolites are not oxidized.
Altogether, these results demonstrate for the first time
pronounced bioenergetic dysfunction in spinal cord from
Abcd1-null mice, at presymptomatic stages (Fig. 3A).
ABCD1 loss decreases pyruvate kinase activity
in spinal cord
The results just shown suggest that the pyruvate steady-
state level is not modified by ABCD1 loss, because its
synthesis and catabolism may be reduced. In addition, we
demonstrated that pyruvate kinase (PKM2) was highly oxi-
dized and its expression reduced in spinal cord from Abcd1 -
mice (Fig. 3C). To investigate whether pyruvate synthesis was
affected, we assessed the activity of pyruvate kinase and
found that it was decreased in spinal cord from 12 month-old
Abcd1 - mice (Fig. 3C). No significant dysregulation of pyru-
vate kinase activity was found in 12 month-old mouse brain
cortex or liver and in spinal cords at an earlier stage (3 months)
(Supplementary Fig. S1).
ABCD1 loss disturbs NADH, NADPH, GSH, and ATP
levels in spinal cord
To study possible global consequences of protein oxidation
on energy homeostasis, we quantified NAD + , NADH,
NADP + , NADPH, and ATP contents (60, 65) in Abcd1 - spinal
cords at 12 months. NADH but not NAD + levels were re-
duced on ABCD1 loss compared with Wt samples (Fig. 4A).
Consequently, the NAD + /NADH ratio was increased (Fig.
4A), thus reflecting an abnormal redox status Moreover, we
observed that NADPH was elevated in Abcd1 - spinal cords at
12 months (Fig. 4B). The levels of reduced glutathione (GSH)
are intimately related to NADPH, because the GSH/GSSG
ratio is determined by the NADPH consuming enzyme Glu-
tathione Reductase (GR) (31, 69). We have, therefore, quan-
tified GSH levels in whole spinal cord extracts, to find out that
GSH levels were reduced in Abcd1 - mice, a situation consis-
tent with increased oxidative stress (Fig. 4C). In addition, we
found that ATP is also reduced in these samples (Fig. 4D),
which directly indicates bioenergetic failure. However,
NAD + , NADH, and ATP levels were not affected in brain
cortex or liver at 12 month of age or in spinal cord at 3 months
of age in Abcd1-null mice, indicating organ specificity and
progressive nature of the metabolic impairment (Supple-
mentary Fig. S2). Altogether, these results point out the spe-
cific importance of ABCD1 in the energy metabolism of the
spinal cord of aged, but still presymptomatic, Abcd1 - mice.
To investigate whether the decrease of ATP could be due to
mitochondrial respiratory chain impairment, we measured
the activity of respiratory chain complexes in spinal cords
FIG. 3. Metabolite levels in 12 month-old spinal cord
from Abcd1-deficient mice. (A) Fructose 1–6 bisphosphate,
dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3
phosphate (GA3P), 2 and 3-phosphoglycerate, pyruvate, lac-
tate, oxalacetate, citrate, a-ketoglutarate, fumarate, and malate
levels in Wt and Abcd1- mice. (B) Pyruvate/lactate ratio is not
modified in Abcd1 - spinal cord at 12m of age. (C) Pyruvate
kinase activity is decreased in 12 month Abcd1-null mice spi-
nal cord. Pyruvate kinase activity is expressed as units/mg
tissue (n = 5–7/genotype). Statistical analysis was done with
Student’s t-test (*p £ 0.05, **p £ 0.01, and ***p £ 0.001).
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extracts from 12 month-old Abcd1 - mice. We quantified the
activities of complex I plus complex III, complex II plus
complex III and complex IV. Activities did not vary between
Abcd1-null and wild type littermates (Supplementary Fig. S3).
A combination of antioxidants prevents oxidative stress
and metabolic failure
We have previously shown that a cocktail of antioxidants
including N-acetylcysteine (NAC), a-lipoic acid (LA), and vi-
tamin E reversed oxidative damage to proteins and DNA,
immunohistological signs of axonal degeneration and associ-
ated locomotor disability in an X-ALD mouse model (38).
To investigate whether these antioxidants were effective in
counteracting oxidative stress to the specific proteins identi-
fied, we treated 8 month-old Abcd1 - mice with a combination
of NAC and LA for 4 months. We have previously reported
that excess of VLCFA decreases reduced glutathione, and
X-ALD cells are more sensitive to glutathione depletion (20).
N-acetylcysteine was chosen, because it can regenerate re-
duced glutathione (GSH) and scavenge several ROS species
including OH$, H2O2, peroxyl radicals, and nitrogen-centered
free radical (28). a-lipoic acid (LA) was chosen, as it can re-
generate GSH from its oxidized counterpart (GS-SG) (3), thus
enhancing the effects of NAC. LA and its reduced form, di-
hydrolipoic acid, may use their chemical properties as a redox
couple to alter protein conformations by forming mixed dis-
ulfides, thus protecting proteins from oxidation. Redox pro-
teomics revealed that the antioxidant treatment prevented
selective oxidation of ALDOA, PGK1, PKM2, DLD, and
ACO2 (Fig. 5A, B).
We also observed that the Abcd1-associated loss of pyru-
vate kinase activity and expression was prevented by NAC
and LA, thereby suggesting that in vivo, the level of oxidation
of this protein may directly correlate with its expression and
enzymatic activity (Fig. 5C, D).
The reduction of NADH, GSH, and ATP levels and the
increase of NADPH were all prevented by antioxidants
Table 1. Metabolite Levels in 12 Month-Old Spinal Cord from Abcd1 - Mice
Metabolite Enzymes Values (mean – SD)
Fold change
(Wt vs. Abcd1 - ) p-Value
Fructose 1,6 bisphosphate Aldolasea Wt = 52776 – 16221
Abcd1 - = 47710 – 8971
- 10% n.s.
DHAP/GA3P Aldolasea Wt = 178258 – 87111
Abcd1 - = 74938 – 44601
- 58% < 0.05
2(or 3)-phosphoglycerate Phosphoglycerate kinasea Wt = 11533 – 4149
Abcd1 - = 5658 – 1460




Wt = 403616 – 132627
Abcd1 - = 462663 – 69665
+ 14% n.s.
Lactate Lactate dehydrogenase Wt = 6253 – 583
Abcd1 - = 6742 – 539
+ 8% n.s.
Oxaloacetate Citrate synthase Wt = 11160 – 3668
Abcd1 - = 11689 – 3076
+ 4% n.s.
Citrate Aconitasea Wt = 6592 – 1799
Abcd1 - = 9747 – 1724




Wt = 76446 – 3633
Abcd1 - = 92223 – 10805
+ 20% = 0.01
Fumarate Fumarase Wt = 16860 – 2531
Abcd1 - = 18587 – 5114
+ 10% n.s.
Malate Malate dehydrogenase Wt = 70599 – 11146
Abcd1 - = 64810 – 17845
- 8% n.s.
Fructose 1–6 bisphosphate, dihydroxyacetone phosphate and glyceraldehyde 3 phosphate (GA3P), 2 and 3-phosphoglycerate, pyruvate,
lactate, oxalacetate, citrate, a-ketoglutarate, fumarate, and malate levels were quantified in Wt and Abcd1 - mice.
aOxidized.
n.s. not significant.
FIG. 4. ABCD1 loss disturbs NADH, NADPH, GSH, and
ATP levels in spinal cord from 12 month-old Abcd1-null
mice. (A) NADH, NAD + levels and NAD + /NADH ratio,
(B) NADPH, NADP + levels and NADP + /NAPH, (C) GSH
levels, and (D) ATP levels in Wt and Abcd1-null mice (n = 8/
genotype). Statistical analysis was done with Student’s t-test:
*p < 0.05, **p < 0.01, ***p < 0.001.
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(Fig. 5E–H), indicating that the treatment was effective in
preventing bioenergetic failure.
Discussion
We have previously suggested that oxidative damage
could be a significant factor contributing to X-ALD patho-
genesis (20, 38, 58). This study corroborates our hypothesis
and points to how energetic failure manifested by diminished
levels of NADH and ATP is most likely due to inhibition of
glycolysis and TCA cycle resulting from the early oxidative
damage to proteins,. Further, our findings strongly suggest
that energetic failure plays a major role in the physiopatho-
genesis of X-ALD, because (i) is progressive and appears
presymptomatically at 12 months of age, in a mouse that ex-
hibits first locomotor disabilities at 20–22 months of age; (ii)
FIG. 5. Metabolic failure is prevented by a combination of antioxidants. (A) Redox proteomics experiments were per-
formed in 12 month-old Abcd1 - and Abcd1 - mice fed for 4 months (Abcd1 - + Antx) with NAC and LA. Western blot with an
antibody anti-DNP was performed to identify oxidized proteins (n = 5/genotype). (B) Western blot (n = 4/genotype) against
aldolase A (ALDO A), phosphoglycerate kinase (PGK1), pyruvate kinase (PKM2), dihydrolipoamide dehydrogenase (DLD),
and mitochondrial aconitase (ACO2). Pyruvate kinase expression (C) and activity (D), NADH, NAD + levels and the NAD + /
NADH ratio (E), NADPH, NADP + levels and NADP + /NADPH ratio (F), GSH levels, (G) and ATP levels (H) were measured
in spinal cord from 12 month-old Wt, Abcd1 - and Abcd1 - mice fed for 4 months with a cocktail of antioxidants (Abcd1 - +
Antx) (n = 6–7 mice per genotype and condition). Statistical analysis was done with ANOVA followed by Tukey HSD post hoc
test. Significant differences are shown as *p < 0.05, **p < 0.01 and ***p < 0.001.
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in vivo antioxidant treatment prevented motor disability and
axonal degeneration (38), and also oxidative damage of im-
portant glycolytic and TCA cycle proteins normalizing
NADH, NADPH, GSH, and ATP levels (Fig. 6).
It has been suggested that oxidative modification of
key mitochondrial TCA enzymes such as pyruvate and a-
ketoglutarate dehydrogenases and aconitase may be an
important pathophysiological factor in neurodegenerative
diseases, by causing mitochondria dysfunction and bioener-
getic failure (8, 32, 43, 60, 65). Indeed, aconitase and KGDHC
are known targets and sources of ROS and their enzymatic
activity is impaired by ROS-induced oxidation (8, 32, 43, 60,
65). Further, increased mitochondrial ROS generation is
thought to induce and stimulate pathogenic feedback cycle by
inactivating sensitive TCA enzymes and impairing NADH and
NADPH generation, which, in turn, results in further impair-
ment of mitochondrial ROS defense capacity, disturbed Ca2 + ,
and ion homeostasis, eventually causing a decrease in ATP
production and overall bioenergetic failure (43, 64, 65).
Of note, we have demonstrated that activities of respiratory
chain are not modified; NADH and ATP levels are lowered
and NADPH is elevated in X-ALD, in vivo in mouse spinal
cord extracts. This tissue contains a mixture of gray and white
matter, where neurons represent *10% of the total amount of
cells, whereas glia is about 90%, with astrocytes being the
most abundant cell type. Energy is mainly produced by mi-
tochondria in neurons, whereas in astrocytes most of ATP is
generated by glycolysis (30). It was reported that, in the gray
matter of the brain, astrocytes export lactate (derived from
glucose or glycogen) to neurons to power their mitochondria.
In the white matter, lactate can support axonal function under
conditions of energy deprivation (53). We, therefore, cannot
exclude the possibility that the results reflect only a sum of
effects in whole tissue and do not reflect a specific disturbance
of a given metabolite or pathway in a particular cell type. For
instance, OXPHOS activities could be impaired in, that is,
neurons. Nevertheless, these results suggest that metabolic
failure is most likely due to impairment in glycolysis and/or
TCA cycle rather than due to damaged mitochondrial respi-
ratory chain. In astrocytes, ATP reduction is probably due to a
defective glycolysis. In neurons, the decrease in ATP levels
could be due to a reduction in NADH generation in mito-
chondria caused by the damage to KGDHC and aconitase
and/or some other unidentified catabolic enzymes. In addi-
tion, the elevation of NADPH could have been caused by an
increased production via Pentose Phosphate Pathway (30)
and/or by an inhibition of Glutathione Reductase (GR) (70).
Indeed, it has been reported that the low glycolytic rate
in neurons results in increased flux through the pentose-
phosphate pathway, thus providing NADPH necessary to
regenerate antioxidant glutathione (30).
The GSH reduction observed, and its recovery on antioxi-
dant treatment, is in line with a major role of GSH in oxidative
stress scenarios, and consistent with previous results: (i) we
formerly showed that X-ALD cells were more sensitive to
GSH depletion and more prone to undergo cell death due to
FIG. 6. Working hypothesis on the interplay between metabolic failure and oxidative stress in X-ALD. C26:0 excess
generates ROS, which results in oxidation of enzymes belonging to glycolysis and TCA cycle. This oxidative damage
provokes a reduction in enzyme activities, which is demonstrated by alteration of the substrate and/or product concen-
trations of these enzymes. An impairment of TCA leads to a reduction in NADH level, the substrate of complex I of the
mitochondria respiratory chain, contributing to decreased production of ATP. This ignites a vicious circle increasing ROS
production. Then, the inhibition of complex I leads to a reduction in ATP production by the mitochondria respiratory chain.
Combination of NAC and LA prevent metabolic failure by protecting key enzymes of TCA and glycolysis from oxidation.
Further, lipoic acid might ameliorate the function of KGDHC and PDHC.
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the oxidative stress-induced damage than the passage-mat-
ched control fibroblasts (20); (ii)Glutathione peroxidase
(GPX1) protein expression was increased in Abcd1 - spinal
cord (20, 38) and normalized by antioxidant treatment (38).
Therefore, GSH reduction is most likely to be caused by an
increased consumption by GPX1 due to an ongoing oxidative
stress process in Abcd1 spinal cords. Oxidative stress has been
classically considered a common event in the neurodegener-
ative cascade in a variety of conditions (37, 40). Ample evi-
dence demonstrates that energy metabolism also plays a
major role in cell death (16, 23). Glycolytic and TCA cycle
proteins such as ALDO A, PGK1, PKM2, DLD, and ACO2 can
be considered as classical targets of oxidative stress, because
the oxidation of these proteins is commonly detected in sev-
eral neurodegenerative disorders (9, 40, 47, 59), although no
‘‘oxidation prone consensus’’ has yet been identified. ALDO A
is oxidized in Parkinson mouse model (59), in amnestic mild
cognitive impairment (MCI), in early onset Alzheimer disease
(EOAD), and in Alzheimer (AD) human brain (9, 40). Oxi-
dized ALDO A has also been detected in progressive supra-
nuclear palsy (PSP) and infantile Parkinson disease (iPD) (40).
PGK1 is oxidized in AD and PD mouse model (59), in MCI
brain (9), and in PSP (40). Moreover, PKM2 is oxidized in MCI
(9) and in Alzheimer brains (9, 40), and a correlation has been
observed between levels of oxidation and activity of PKM2 in
MCI brain (10), and in a rat hepatoma cellular model (27). In
agreement with this observation, we demonstrate here that
PKM2 is oxidized and its activity decreased in Abcd1-null
mice. Nevertheless, as PKM2 expression is also decreased in
our samples, we cannot determine whether this reduction in
activity is due to oxidative stress or PKM2 protein levels.
Unfortunately, no information on PKM2 expression is avail-
able in patients with MCI or patients with Alzheimer (9, 10,
40), but our result suggest that its expression levels would be
worth checking. The mechanisms by which reduction in ex-
pression of PKM2 occur deserve further investigation. The
decrease in ATP levels that we are reporting in this study is
likely due to a mitochondria dysfunction. Indeed, ATP is
mainly produced by mitochondria in nonproliferating, post-
mitotic cells; whereas it is preferentially generated by gly-
colysis in proliferating, for example, cancer cells (19).
Evidence of ultrastructural anomalies of mitochondria in
spinal neurons of Abcd1 - mice have been reported (18); this is
consistent with previous findings of mitochondria alterations
in liver of peroxisomal deficient models (5). According to the
findings in a mouse model of AD, glycolysis induction could
be a mechanism to compensate for mitochondria dysfunction
as a metabolic reprogramming (68). However, this repro-
gramming cannot be efficient in Abcd1 - spinal cord, because
ALDO A, PFK1, and PKM2 are oxidized and their activity
might be altered. It was also reported that aconitase is oxidized
in both PD and AD mouse models (59), in AD (9), and in
Huntington’s disease (40). Further, the oxidation of DLD had
been shown in two PD mouse models (59). Although some
specific oxidized proteins have been identified in neurode-
generative disorders, a large number of oxidized proteins are
more commonly found (9, 40, 59). This could be due to limi-
tations of proteomics experiments. Indeed, only proteins that
are very well expressed can be identified by 2D gel proteomics
(56). Indeed, the Western-blot anti-DNP detect as little as 1
pmol carbonyl in a protein sample and require a minimum of
as little as 50 ng protein oxidized to the extent of 0.5 mol car-
bonyl/mol protein. Moreover, intrinsic limitations to 2D gels
techniques include, for instance, that proteins migrating out-
side a pH scale from 3 to 11 and having a molecular weight
outside the range of 25–100 kD cannot be detected. Similarly,
membrane-located or highly hydrophobic proteins cannot be
resolved by this technique. Low-abundance proteins cannot be
identified due to lowered sensitivity of MALDI-TOF sequenc-
ing. Moreover, many of these proteins are generally considered
as house-keeping agents, having an essential function in
maintenance of cell viability. In addition, in the case of neurons,
for instance, it was shown that oxidative injury affects a large
number of substrates including enzymes of the glycolysis and
TCA cycle, thus resulting in a weakened energy metabolism
(23). As a result, reduced ATP production in affected neurons
reduces their capacity to respond to physiological energy de-
mands such as synaptic input or axonal transport, which might
lead to axonal degeneration in our particular disease scenario,
or to progressive neuronal dysfunction in the most frequent
neurodegenerative diseases (16).
Ample evidence indicates that oxidative damage to pro-
teins related to energy metabolism is accompanied by the
corresponding detriment of their function and impaired bio-
energetics as observed in Alzheimer’s and Parkinson’s dis-
eases (9, 16, 40, 59). Most commonly, this failure is manifested
by a decrease in cellular ATP, as in AD (52), PD (25), and ALS
(7). Less evidence is available about NADH levels. A signifi-
cant decrease in both reduced and oxidized forms of NAD
and an increase in NAD + /NADH ratio was reported in the
brains of Ataxia-telangiectasia mouse model (61). It was also
shown that oxidative products generated by dopamine were
able to reduce NADH levels in isolated mitochondria (6). Both
NADH and NADPH levels were decreased in neurons cul-
tured from aged (24 month-old) rats (46). Moreover, it was
shown that H2O2 decreased NADH levels in nerve terminals
(64) and increased NAD + /NADH ratio in neonatal heart
muscle cells (33), but their ratios have not been systematically
measured in most prevalent neurodegenerative diseases.
The widely used antioxidants LA and NAC have been
shown to increase the level of GSH and affect the regulation of
various redox signalling pathway in cells (15, 44). Combined
antioxidant therapy aims at reproducing the multistep, com-
bined response, which is observed in vivo leading to recovery
after an oxidative challenge (35). Some studies have shown
that combinations of antioxidants can be beneficial for pa-
thologies associated with increased oxidative stress (55) and
that such a strategy might be advantageous over higher doses
of single antioxidants for treating mitochondriopathies (62,
63), reproducing what it is already present in nature; that is, a
combination of antioxidant systems rather than a single one.
In particular, it has been recently demonstrated that several
combinations of antioxidants {[LA, NAC and vitamin E (4)],
[LA and NAC (41)], or [LA and acetyl-L-carnitine (1, 57)]} are
able to prevent oxidative damage and improve mitochondrial
ultrastructural decay or dysfunction in Alzheimer disease
mouse models (57), and even in some clinical studies (13, 51).
Further, since LA is an essential cofactor of PDHC and
KGDHC, its supplementation could protect and increase the
enzymatic activity of KGDHC (2), and, therefore, help bring
about an increase in NADH and ATP production. Indeed, we
demonstrate in this study that the improvement in disability
and axonal degeneration in X-ALD mice by LA and NAC as
shown elsewhere (38) correlates with a decrease in oxidation
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damage of key proteins involved in metabolic homeostasis,
and with preserved NADH and ATP levels. Thus, our results
provide new insights into the molecular mechanisms of action
of antioxidants in X-ALD.
Moreover, we have identified new markers of pathology in
the Abcd1 - mice such as PKM2 expression level and activity,
NADH, and ATP levels. These markers may become very
useful to monitor the efficiency of treatments in preclinical
trials in X-ALD mice. Monitoring of the biological effects of
the drugs in patients would be further facilitated by the recent
identification by MS/MS of quantitative biomarkers of oxi-
dative damage to proteins in the peripheral blood mononu-
clear cells from patients with X-ALD (22). Therapeutic
implications derived from this work could be extrapolated to
other diseases in which energy metabolic failure due to oxi-
dative stress is a main or early contributing pathogenic factor.
Materials and Methods
Antibodies
The following antibodies were used for western blots: anti-
rabbit DNP (D9659, [Sigma]), dilution 1/500; anti-mouse
c-tubulin, dilution: 1/5000 (T6557, clone GTU-88 [Sigma]);
anti-rabbit pyruvate kynase, dilution 1/500 (ab-38237 [Ab-
cam]); anti-rabbit aldolase, dilution 1/1000 (NB600-915 [Novus
Biologicals]); anti-rabbit-phosphoglycerate kinase 1, dilution
1/250 (AB38007 [Abcam]); anti-rabbit aconitase 2, dilution 1/
1000 (ACO2-AP1936c [Abgent]); and anti-rabbit lipoamide
dehydrogenase, dilution 1/1000 (L2498-05 [US Biological]).
Goat anti-rabbit IgG linked to horseradish peroxidase, dilution:
1/15000 (P0448 [Dako]) and Goat anti-mouse IgG linked to
horseradish peroxidase, dilution: 1/15000 (G21040 [Invitro-
gen]) were used as secondary antibodies.
Mouse breeding
The generation and genotyping of Abcd1 - mice has previ-
ously been described (39, 49, 50). Mice used for experiments
were of a pure C57BL/6J background, all male. Animals were
sacrificed, and tissues were recovered and conserved at
- 80C. All methods employed in this study were in accor-
dance with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH Publications No. 85–23, revised 1996) and with the ethical
committee of IDIBELL and the Generalitat de Catalunya.
Treatment of mice
a-Lipoic acid (LA) (0.5% w/w) was mixed into AIN-76A
chow from Dyets (Bethlehem, PA). N-acetylcysteine (1%) was
dissolved in water (pH 3.5) (38).
Eight-month-old animals were randomly assigned to one
of the following dietary groups for 4 months. Group I (Wt): Wt
mice (n = 8) received only normal AIN-76A chow, Group II
(Abcd1 - ) Abcd1 - mice (n = 8) received only normal AIN-76A
chow, and Group III (Abcd1 - + Antx [Antioxidant]) Abcd1 -
mice (n = 6) were treated with chow containing LA and with
NAC in drinking water (38).
Cell culture and treatments
Control from healthy donors (n = 5) and X-ALD human fi-
broblasts (n = 5) were obtained after informed consent at the
Bellvitge University Hospital. Cells were treated in medium
containing FCS (10%) at 37C in humidified 95% air/5% CO2.
After the growing period, the medium was changed to serum-
free medium supplemented with 100 lM BSA (free fatty acid)-
bound fatty acid for 7 days at a 2:1 C26:0 fatty acid/BSA ratio.
Untreated cells received an amount of BSA equal to that
grown with the BSA-fatty acid complex. No significant
changes in morphology were observed during incubation in
serum-free medium (Supplementary Fig. S4). Unless other-
wise stated, experiments were carried out with cells at 95% of
confluence. Lines were used on passages 12–18.
Monodimensional electrophoresis and western blotting
Tissues were removed from euthanized mice and flash-
frozen on liquid nitrogen. Frozen tissues and human fibro-
blasts samples were homogenized in RIPA buffer using a
motor-driven grinder (Sigma-Aldrich) and then sonicated for
2 min at 4C in an Ultrasonic processor UP50H (Hielscher-
Ultrasound Technology). Ten to 100 lg were loaded on to
each lane of 10% polyacrylamide gels for 60 min at 120 mV.
Resolved proteins were transferred onto nitrocellulose mem-
brane. Proteins were detected with ECL western blotting
analysis system followed by exposure to CL-XPosure Film
(Thermo Scientific). Autoradiographs were scanned and
quantified using GS800 Densitometer (Bio-Rad).
Two-dimensional electrophoresis and western blotting
Spinal cord and human fibroblast samples were homoge-
nized in a lysis buffer (180 mM KCl, 5 mM MOPS, 2 mM
EDTA, 1 lM butylated hydroxytoluene, and protease inhibi-
tor cocktail [Roche Diagnostics GmbH]) using a motor-driven
grinder, sonicated for 2 min at 4C in a Ultrasonic processor
UP50H, and then centrifuged for 5 min at 1000 g. Afterward,
the supernatant was collected and a new centrifugation
(5 min, 1000 g) was carried out. After quantification, 1 mg of
protein was precipitated with 20% TCA, and the pellet was
resuspended in 200 ll of a denaturizing buffer (9 M urea, 4%
CHAPS). Proteins were newly quantified, and 100–200 lg of
proteins was dissolved in IEF (Isoelectric focusing) buffer (9 M
urea, 4% CHAPS, 1% bromophenol blue, 50 mM DTT, and
0.5% ampholites (pH 3-11NL (GE Healthcare Bio-Sciences
AB) up to 340 ll. This solution was applied overnight to 3–11
NL 18 cm IPG strips (GE Healthcare Bio-Sciences AB, Up-
psala, Sweden). Isoelectric focusing migration was performed
as follows: 250 V for 5h, followed by a linear gradient to 60,000
V, and then 250 V for 1 h in a Bio-Rad system. Strips were
derivatized in a solution of 0.2% DNPH in HCl 2 N for 10 min
and then equilibrated in 2 M TrisHCl-30% glycerol buffer for
15 min. For the last two steps of re-equilibration, strips were
first incubated in a buffer containing 6 M urea, 2% SDS, 20%
glycerol, 0.13 M DTT, and 0.375 M TrisHCl pH 8.8 for 10 min
and then in the same buffer containing 2.5% iodoacetamide
for 10 min. The equilibrated strips were loaded in a 10% SDS-
PAGE gel (20 · 20 cm) and run at 250 V for 4 h at RT. For
oxyblot, proteins were transferred on to nitrocellulose mem-
branes and then detected with ECL western blotting analysis
system followed by exposure to CL-XPosure Film (Thermo
Scientific). This method is based on the formation of a hy-
drazone (DNP) resulting from the reaction of protein-bound
carbonyl and 2,4-dinitrophenylhydrazine. An antibody
against DNP is used to detect carbonylated proteins (54).
Thereby, we performed two-bidimensional (2D) gels in
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parallel. The first gel was silver stained to detect whole pro-
teins, and the second one was transferred on to nitrocellulose
membrane to detect oxidized protein. However, before the
second electrophoresis migration and the transfer on to ni-
trocellulose membrane, samples were derivatized on to the
strips with 2,4-dinitrophenylhydrazine (DNPH) after the first
isoelectric focusing migration (Fig. 1A). Then, differentially
oxidized cut spots were digested with trypsin (DigestPro MS),
and peptides were analyzed by MS. Peptide Mass Finger-
printing database was used to identify proteins from a spec-
trum generated by MS (Supplementary Table S1). For silver
staining, 2D gels were fixed for 30 min in a solution containing
30% ethanol and 70% glacial acetic acid. The fixing solution
was replaced with sensitizing solution consisting of 30%
ethanol, 0.2% w/v sodium thiosulphate, and 6.8% w/v so-
dium acetate. After 30 min, the sensitizing solution was re-
moved, and the gels were washed thrice with distilled water
for 5 min. The gels were stained with a silver solution con-
taining 2.5 g/l of silver nitrate for 20 min and then washed
twice with distilled water for 1 min. The gels were put in a
solution of sodium carbonate 2.5% w/v. To arrest the devel-
oping process, solution was removed and the reaction was
stopped with a solution containing EDTA-Na2 1.26% w/v.
Fold difference was statistically compared among the five
independent experiments. Proteins for further investigation
were selected on the basis of their higher oxidation values
when comparing Wt versus Abcd1 - (Supplementary Fig. S5).
Protein identification
Proteins were identified in the Proteomic Unit of Institut de
Recerca Vall d’Hebron (Barcelona) (Supplementary Table S1).
Detailed methodology is described in the Supplementary Methods.
Metabolomics
Metabolites were extracted from homogenate tissues with
methanol as previously described (67). Briefly, 60 ll of cold
methanol was added to 20 ll of homogenate (containing
1.85 lg protein), vortexed for 1 min, and incubated at - 20C
for 1 h to precipitate proteins. Samples were centrifuged for
3 min at 12,000 g, and the supernatant was collected. The su-
pernatant was dried in a SpeedVac and resuspended in 50 ll of
water. The sample was filtered in an eppendorf UltraFree 5 kDa
filter. Four microliters of extracted sample was applied to a
reverse-phase column (C18 Luna 3n pfp(2) 100A 150*2 mm,
Phenomenex). The flow rate was 200 ll/min with solvent A
composed of water containing 0.1% formic acid for positive
ionization or 0.1% acetic acid for negative ionization, and sol-
vent B composed of 95% acetonitrile and 5% water containing
corresponding counterions. The gradient consisted of a gradi-
ent of solvent B from 5% to 100% in 20 min, held at 100%
solvent B for 5 min, and re-equilibrated at 5% solvent B for
6 min. Data were collected in positive electrospray mode in a
QTOF (Agilent) operated in full-scan mode at 100–3000 m/z.
The capillary voltage was 3500 V with a scan rate of 1 scan/s.
N2 was used as a gas nebulizer (flow was 5 l/min and tem-
perature was 350C). We used the MassHunter Data Analysis
Software (Agilent) to collect the results and the MassHunter
Qualitative Analysis (Agilent) to perform the integration and
metabolite quantitation. The identity of metabolites was con-
firmed by identity of mass, isotopic distribution, and coelution
with authentic standards. The m/z values used for quantifica-
tion were m/z 394.9781 [2M + Na] + for 2 (or 3) phosphoglyc-
erate, m/z 176.0546 [2M + NH4 + -H2O] + for pyruvate, m/z
229.0133 [M + CH3COO] - for DHAP/GA3P, m/z 193.0343
[M + H]+ for citrate, m/z 292.0662 [2M + NH4] + + [-H2O] for
a-ketoglutarate, m/z 338.9888 [M-H - ] - for fructose-1,6-
biphosphate, m/z 115.0038 [M-H - ] - for fumarate, m/z 133.0136
for malate, m/z 112.5880 [M-H- ] - for oxalacetate, and m/z
179.0547 [2M-H - ] - for lactate. In all cases, D between calcu-
lated molecular weight (M.W.) and detected masses was lower
than 0.001 Da. The identity of all metabolites was confirmed by
identical chromatographic and mass spectrometric properties
(molecular weight and isotopic distribution) of the quantified
metabolites in comparison with authentic standards.
ATP levels
Mice were sacrificed by cervical dislocation, and spinal cords
were immediately frozen in liquid nitrogen and stored at
- 80C. ATP was extracted with cold perchloric acid (10%)
from 10 mg of spinal cord, neutralized with KOH, and centri-
fuged (34). Then, ATP concentrations were quantified in trip-
licate per animal using the ATPlite 1 step (PerkinElmer)
according to the manufacturer’s protocol. Data were normal-
ized to mg of proteins. All assays were performed in triplicate.
NAD-NADH and NADP-NADPH determinations
NAD + , NADH and NADP + , NADPH were, respectively,
quantified by the NAD and NADP cycling assay. Detailed
methodology is described in the Supplementary Methods.
Q-TOF based GSH analyses
Spinal cord samples were homogenate with a buffer con-
taining 200 mM methane sulphonic acid with 5 mM DTPAC.
Detailed methodology is described in Supplementary Methods.
Respiratory chain activity
We quantified the activities of complex I plus complex III,
complex II plus complex III, complex IV, and Citrate synthase
in the spinal cord samples from 12 month-old Abcd1 - mice.
Detailed methodology is described in Supplementary Methods.
Pyruvate kinase activity
Pyruvate kinase activity was determined by a spectro-
photometrical method as previously described (26). 15 lg of
mitochondria-free supernatant was added to a 0.2 ml of re-
action buffer (50 mM TrisHCl pH 7.4, 100 mM KCl, 20 mM
MgCl2, 0.3 mM NADH, 4 mM ADP, 1 mM phosphoenolpyr-
uvate (PEP), and 5 units/ml of lactate dehydrogenase [LDH]).
NADH was spectrophotometrically recorded after 6 min
at 340 nm in a microplate spectrophotometer (PowerWave
Microplate Spectrophotometer, BioTek). All assays were
performed in triplicate at room temperature. Results were
expressed as units (lmol/min) per mg tissue.
RNA extraction and quantitative real-time PCR
Total RNA was extracted using RNeasy Kit (Qiagen), and
Q-PCR experiments were performed according to manufac-
turer’s instructions (LightCycler, Roche Diagnostics) as pre-
viously described (21). PCR were carried out with 36b4 (also
called Rpl0) used as a standard gene. The nucleotide se-
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quences of primers are available (Supplementary Table S2).
Data are given as mean – SD.
Statistical analysis
Data are given as mean – SD. Significant differences were
determined by one-way ANOVA followed by Tukey HSD post
hoc test after verifying normality (*p < 0.05, **p < 0.01,
***p < 0.001) or Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.001).
Statistical analyses were performed using SPSS 12.0 program.
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EOAD¼ early onset Alzheimer disease
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iPD¼ infantile Parkinson disease
KGDHC¼ a-ketoglutarate dehydrogenase complex
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ROS¼ reactive oxygen species
TCA¼ tricarboxylic acid
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